Labetalol

This classification denotes an adrenergic antagonist with the molecular formula C19H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5H8897N95, chemically known as benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)- but generally known as labetalol, which bears US NIH Compound Identifier 3869. European Medicines Agency schedules Labetalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08382MIG. The term LABETALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules labetalol in its Anatomical Therapeutic Chemical (ATC) Classification. LABETALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule labetalol under HS 29242995 and SITC 51479. As of Q4 2014, LABETALOL remains the US FDA Preferred Term for this commodity. Labetalol bears US NLM identifiers UMLS ID C0022860 and NCI Concept Code C29146. SMILES: OC(CNC(CCC1CCCCC1)C)C1CC(C(O)CC1)C(=O)N.